Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

被引：0

作者：

Ito, Mamoru ^{[1
]}

Okumura, Yuta ^{[2
]}

Nio, Kenta ^{[3
]}

Baba, Eishi ^{[4
]}

Ozaki, Yukinori ^{[5
]}

Nishio, Hiroshi ^{[6
]}

Ichihara, Eiki ^{[7
]}

Miura, Yuji ^{[8
]}

Endo, Makoto ^{[9
]}

Yano, Shingo ^{[10
]}

Maruyama, Dai ^{[11
]}

Yoshinami, Tetsuhiro ^{[12
]}

Susumu, Nobuyuki ^{[13
]}

Takekuma, Munetaka ^{[14
]}

Motohashi, Takashi ^{[15
]}

Ochi, Nobuaki ^{[16
]}

Kubo, Toshio ^{[17
]}

Uchino, Keita ^{[18
]}

Kimura, Takahiro ^{[19
]}

Kamiyama, Yutaro ^{[20
]}

Nakao, Shinji ^{[21
]}

Tamura, Shinobu ^{[22
]}

Nishimoto, Hitomi ^{[23
]}

Kato, Yasuhisa ^{[24
]}

Sato, Atsushi ^{[25
]}

Takano, Toshimi ^{[5
]}

Tsuchihashi, Kenji ^{[1
]}

机构：

[1] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, 3-1-1 Maidashi,Higashi ku, Fukuoka 8128582, Japan

[2] NHO Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[3] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Oncol & Social Med, Fukuoka, Japan

[5] Japanese Fdn Canc Res, Dept Breast Med Oncol, Canc Inst Hosp, Tokyo, Japan

[6] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan

[7] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[9] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan

[10] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol Hematol, Tokyo, Japan

[11] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[12] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan

[13] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan

[14] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka, Japan

[15] Tokyo Womens Med Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[16] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan

[17] Okayama Univ Hosp, Dept Allergy & Resp Med, Okayama, Japan

[18] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan

[19] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[20] Jikei Univ, Sch Med, Dept Clin Oncol Hematol, Tokyo, Japan

[21] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Kanazawa, Ishikawa, Japan

[22] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan

[23] Okayama Univ Hosp, Dept Nursing, Okayama, Japan

[24] Shonan Univ Med Sci, Fac Pharmaceut Sci, Dept Drug Informat, Kamakura, Kanagawa, Japan

[25] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Aomori, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 06期

关键词：

G-CSF; Febrile neutropenia; Digestive system tumor; FEBRILE NEUTROPENIA; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; OPEN-LABEL; PHASE-III; CANCER; RECOMMENDATIONS; PEGFILGRASTIM; FOLFIRINOX; GEMCITABINE;

D O I：

10.1007/s10147-024-02502-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundGranulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology.MethodsThis systematic review addressed two main clinical questions (CQ): CQ1: "Is primary prophylaxis with G-CSF effective in chemotherapy?", and CQ2: "Is increasing the intensity of chemotherapy with G-CSF effective?" We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations.ResultsAfter two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records.ConclusionThe use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.

引用

页码：689 / 699

页数：11

共 50 条

[31] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
Vitolo, Umberto
Angrili, Francesco
DeCosta, Lucy
Wetten, Sally
Federico, Massimo
MEDICAL ONCOLOGY, 2016, 33 (12)
[32] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin’s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
Umberto Vitolo
Francesco Angrili
Lucy DeCosta
Sally Wetten
Massimo Federico
Medical Oncology, 2016, 33
[33] USE OF BIOSIMILAR G-CSF FOR PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA: POOLED ANALYSIS OF CLINICAL USAGE STUDIES
Gascon, P.
Tesch, H.
Verpoort, K.
Rosati, M. S.
Salesi, N.
Barker, H.
Agrawal, S.
Muenzberg, M.
Turner, M.
ANNALS OF ONCOLOGY, 2012, 23 : 502 - 503
[34] Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022
Yokoe, Takamichi
Yoshinami, Tetsuhiro
Nozawa, Kazuki
Ozaki, Yukinori
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miura, Yuji
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 674 - 683
[35] Delayed Granulocyte Colony-Stimulating Factor (G-CSF) Administration after Chemotherapy Reduces Total G-CSF Doses without Affecting Neutrophil Recovery in a Randomized Clinical Study in Children with Solid Tumors
Yankelevich, Maxim
Hoogstra, David J.
Abrams, Judith
Chu, Roland
Bhambhani, Kanta
Taub, Jeffrey W.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2020, 37 (08) : 665 - 675
[36] APPROPRIATE USE OF G-CSF IN CANCER TREATMENT: AN EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE-2013
Usui, Noriko
ANNALS OF ONCOLOGY, 2014, 25
[37] Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study
Jacot, William
Antoine, Eric-Charles
Hacini, Maya
Giron, Cathy
Riviere, Alain
Moureau-Zabotto, Laurence
Cassin, Daniel
Yazbek, Gabriel
Orfeuvre, Hubert
Sakek, Nacera
Diab, Rafik
Bastit, Laurent
Mille, Dominique
Azria, David
BULLETIN DU CANCER, 2015, 102 (12) : 979 - 992
[38] G-CSF Prophylaxis in High-Risk Female Patients with solid Tumors in clinical Practice: IMPACT SOLID Study
Vavra, C.
Singer, C.
Staudigl, C.
Hubalek, M.
Unterrieder, K.
Jaeger, C.
Sevelda, P.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2012, 72 (04)
[39] Use of G-CSF during acute on chronic liver failure: Clinical and biochemical safety profile
Novi, M.
Zocco, M. A.
Di Campli, C.
Di Gioacchino, G.
Rutella, S.
Rinninella, E.
Ainora, M. E.
Leone, G.
Gasbarrini, G.
Rapaccini, G. L.
Pola, P.
Gasbarrini, A.
JOURNAL OF HEPATOLOGY, 2007, 46 : S143 - S143
[40] DELAYED GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION FOR CHEMOTHERAPY INDUCED NEUTROPENIA REDUCES TOTAL G-CSF DOSES WITHOUT AFFECTING NEUTROPHIL RECOVERY IN A RANDOMIZED CLINICAL STUDY
Hoogstra, David
Chu, Roland
Bhambhani, Kanta
Yankelevich, Maxim
Taub, Jeffrey
PEDIATRIC BLOOD & CANCER, 2016, 63 : S7 - S7

← 1 2 3 4 5 →